Oncobiomix
Oncobiomix Inc.
Oncobiomix Inc. is an early-stage biotechnology company leveraging artificial intelligence and microbiome analysis for the early detection of cancer. The company's primary focus is the development of a non-invasive diagnostic test that analyzes gut microbiome biomarkers to assess an individual's risk for prostate cancer.
Products & Team
PRIMUS (Prostate Cancer Risk Insight through Microbiome Understanding)
PRIMUS is a non-invasive prostate cancer biomarker test currently in the research and validation phase. The process involves a self-collected stool sample being sent to an affiliated lab, where a proprietary algorithm analyzes unique biomarkers in the gut microbiome to assess an individual's risk of developing or progressing with prostate cancer.
For men undergoing prostate cancer screening or on active surveillance, the PRIMUS test provides a non-invasive method for assessing cancer risk, which can help guide wellness decisions and potentially reduce the need for more invasive diagnostic procedures.
Addresses the need for less invasive, more informative risk assessment tools beyond traditional screening methods like PSA tests and biopsies, especially for patients in a "watch and wait" scenario.